Literature DB >> 15634896

Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.

Jianda Yuan1, Jean-Baptiste Latouche, John L Reagan, Glenn Heller, Isabelle Riviere, Michel Sadelain, James W Young.   

Abstract

Sustained Ag expression by human dendritic cells (DCs) is an attractive means of optimizing Ag presentation for stimulating durable cellular immunity. To establish proof of principle, we used Langerhans cell (LC) progeny of retrovirally transduced CD34(+) hemopoietic progenitor cells to stimulate responses against the HLA-A*0201-restricted influenza matrix peptide (fluMP). Retroviral transduction of CD34(+) hemopoietic progenitor cells, during pre-expansion by thrombopoietin, c-kit ligand, and FLT-3 ligand, on recombinant fibronectin, but in the absence of FCS, resulted in gene expression by 20-30% of the LCs. Expression persisted at least 28 days, with little decline (<30%) over that time. Retroviral transduction did not alter the phenotype or potent immunogenicity of normal mature DCs. FluMP-transduced LCs stimulated a 130-fold expansion of T cells reactive with HLA-A*0201-fluMP tetramers, even at LC:T cell ratios of 1:100-150 and lower, whereas fluMP-pulsed LCs stimulated only a 30-fold expansion. FluMP-transduced LCs also stimulated higher IFN-gamma secretion (100-123 spot-forming cells/10(5) CD8(+) T cells) than did fluMP-pulsed LCs (10-91 spot-forming cells/10(5) CD8(+) T cells). CD8(+) T cells stimulated by transduced LCs did not react preferentially with retrovirally transduced targets, indicating that the responses targeted only the immunizing influenza and not the retroviral vector Ags, even though these could have provided nonspecific helper epitopes presented by the transduced LCs. These data demonstrate that gene-transduced LCs maintain the activated phenotype as well potent immunogenicity typical of mature DCs. LCs genetically modified to express fluMP are also more potent stimulators of Ag-specific CD8(+) T cell responses than are peptide-pulsed LCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634896     DOI: 10.4049/jimmunol.174.2.758

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.

Authors:  Victor D Fedorov; Maria Themeli; Michel Sadelain
Journal:  Sci Transl Med       Date:  2013-12-11       Impact factor: 17.956

2.  A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitopes for adoptive therapy.

Authors:  Aisha N Hasan; Wouter J Kollen; Deepa Trivedi; Annamalai Selvakumar; Bo Dupont; Michel Sadelain; Richard J O'Reilly
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

Review 3.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

Review 4.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

5.  Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo.

Authors:  Jinhong Guo; Yaoyao Zhang; Qiuhong Qin; Naixia Chao; Tianming Huang; Chengxiao Chen; Xiaoling Lu; Rongshi Huang; Jian Pan
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

6.  Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Authors:  Lazar Vujanovic; Theresa L Whiteside; Douglas M Potter; Jessica Chu; Soldano Ferrone; Lisa H Butterfield
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

7.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

8.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

9.  Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic; Patricia M Santos; Deena M Maurer; Andrea Gambotto; Joel Lohr; Chunlei Li; Jacob Waldman; Uma Chandran; Yan Lin; Huang Lin; Hussein A Tawbi; Ahmad A Tarhini; John M Kirkwood
Journal:  J Immunother Cancer       Date:  2019-04-24       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.